FDA seeks osteoporosis trial design comments
FDA is seeking comments to modify 11994 draft guidance on osteoporosis clinical trial design. FDA's 2notice asks "do fracture endpoint trials need to be three years in duration, or could shorter studies provide adequate evidence of a new osteoporosis drug's effectiveness and safety?" and "is it appropriate to use placebo controls in fracture endpoint trials?" An advisory committee generally agreed that such studies could be conducted ethically among low-risk patients (3"The Pink Sheet" Sept. 30, 2002, p. 17)...
You may also be interested in...
FDA's revised osteoporosis drug guidance should use fracture reduction as a primary endpoint, while increases in bone mineral density should remain a surrogate endpoint, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Sept. 25
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.